ホジキン病におけるインスリン受容体抗体による低血糖症
Lancet (London, England)
|January 31, 1987
まとめ
ホッジキン病の患者は,インスリン受容体抗体により重度の低血糖症を発症した. この自己抗体はインスリン効果を模倣し,血糖の危険な低下を引き起こした.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 腫瘍免疫学について
- メタボリック障害 メタボリック障害
背景:
- ホッジキン病の化学療法は,複雑な代謝的副作用をもたらす可能性があります.
- 禁食中の低血糖症は,調査を義務付ける希少だが深刻な合併症である.
研究 の 目的:
- ホジキン病の患者における重度の断食低血糖症の原因を調査する.
- 低血糖症の原因となる患者の血清にある因子の性質を特定する.
- この因子がグルコース代謝に及ぼす作用のメカニズムを探求する.
主な方法:
- ネズミの脂肪細胞におけるグルコース吸収の測定.
- 血清の免疫グロブリン分子の分離.
- ヒトの赤血球にインスリン結合の調査.
- ヒトの胎盤抽出物を用いてインスリン受容体の降水とリン酸化の分析.
主要な成果:
- 患者の血清には,脂肪細胞のグルコース吸収を刺激する因子が含まれていた.
- この因子は,免疫グロブリン分数に局在していた.
- 血清因子は結合インスリンを異動させ,インスリン受容体と相互作用した.
- 証拠によると,その要因はインスリン受容体に対する自己抗体であった.
結論:
- 患者の低血糖症は,インスリン受容体を標的とした自己抗体によって引き起こされた.
- この自己抗体は,インスリンのような活性を示します.
- このケースは,ホジキン病における珍しいパラネオプラスティックまたは治療に関連する自己免疫合併症を強調しています.
関連する概念動画
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...


